YOLFTbeta
Innoviva Inc

Innoviva Inc

INVA · NASDAQ · Healthcare / Biotechnology

19.03USD+0.06 (+0.32%)

Price History

Full chart

Market Stats

Previous Close18.97
Open19.11
Day Range18.95 – 19.23
52-Week Range16.52 – 25.15
Volume560.90K
Market Cap1.50B
P/E (TTM)4.81
Forward P/E8.54
EPS4.31
Dividend Yield0.00%
Beta0.33
50-Day Avg21.09
200-Day Avg21.76

About

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Pavel Raifeld C.F.A.
  • Employees159
  • Headquarters1350 Old Bayshore Highway, Burlingame, CA, United States, 94010, USA
  • Websitehttps://www.inva.com

Leadership

  • Mr. Pavel Raifeld C.F.A.CEO & Director · b. 1984
  • Mr. Stephen Basso M.B.A.Chief Financial Officer · b. 1966
  • Ms. Marianne Zhen CPAChief Accounting Officer & Secretary · b. 1969
  • Ms. Patricia M. DrakeChief Commercial Officer-Innoviva Specialty Therapeutics, Inc. · b. 1967
  • Dr. David Altarac M.D., MPAChief Medical Officer of IST · b. 1962

Financials

Income Statement

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--156.00K3.60M8.94M12.05M19.59M22.00M23.10M24.37M24.22M24.51M5.61M4.53M8.43M53.95M133.57M217.22M261.00M261.02M336.79M391.87M331.34M310.46M358.71M425.13M
Growth (%)---+2210.90%+147.99%+34.83%+62.49%+12.33%+4.97%+5.53%-0.62%+1.19%-77.10%-19.26%+86.08%+539.74%+147.58%+62.63%+20.16%+0.00%+29.03%+16.35%-15.45%-6.30%+15.54%+18.52%
Cost of Revenue43.19M-78.11M70.86M110.52M157.50M194.56M186.51M106.38M100.29M98.65M130.45M8.15M9.04M7.50M2.62M1.39M1.35M0-1.79M13.83M13.79M42.64M36.60M117.61M
Gross Profit-43.19M-156.00K3.60M8.94M12.05M19.59M22.00M23.10M24.37M24.22M24.51M-2.54M-4.51M935.00K51.33M132.18M217.22M261.00M261.02M336.79K391.87M317.55M267.82M322.11M307.52M
Gross Margin--100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%100.00%-45.25%-99.43%11.09%95.15%98.96%100.00%100.00%100.00%0.10%100.00%95.84%86.27%89.80%72.33%
Operating Expense60.74M-83.24M76.07M111.33M161.61M198.76M190.57M110.88M104.59M102.55M134.25M10.46M24.29M34.86M19.75M23.19M33.61M22.75M14.66M-320.79M16.76M110.55M153.94M155.25M143.77M
Operating Income-103.93M-74.41M-83.08M-72.47M-102.39M-149.56M-179.17M-168.56M-87.78M-80.22M-78.32M-109.74M-13.00M-28.80M-33.93M31.58M108.99M183.60M238.25M246.36M321.12M375.10M207.00M113.89M166.87M163.75M
Operating Margin---53258.33%-2010.15%-1145.36%-1240.72%-914.74%-766.13%-380.09%-329.10%-323.34%-447.69%-231.59%-635.37%-402.34%58.54%81.60%84.53%91.28%94.39%95.35%95.72%62.47%36.68%46.52%38.52%
EBITDA-94.94M-53.77M-77.96M-67.26M-97.02M-145.45M-174.97M-164.51M-81.00M-74.67M-71.48M-101.74M-21.89M-149.66M-24.46M45.51M122.94M191.73M236.81M231.72M317.00M361.36M308.32M235.04M85.50M383.79M
EBITDA Margin---49973.72%-1865.66%-1085.22%-1206.65%-893.31%-747.69%-350.71%-306.37%-295.10%-415.06%-390.08%-3302.29%-290.09%84.36%92.04%88.26%90.73%88.78%94.12%92.22%93.05%75.71%23.84%90.28%
Net Income-94.94M-64.84M-79.23M-70.58M-102.65M-143.16M-166.04M-160.00M-93.64M-85.30M-83.86M-115.34M-18.54M-170.70M-168.46M-18.76M59.54M134.14M395.06M157.29M224.40M265.85M213.92M179.72M23.39M271.17M
Net Income Margin---50786.54%-1957.92%-1148.26%-1187.69%-847.73%-727.19%-405.45%-349.97%-346.21%-470.56%-330.34%-3766.57%-1997.68%-34.77%44.57%61.76%151.36%60.26%66.63%67.84%64.56%57.89%6.52%63.78%
R&D49.80M53.77M66.48M61.70M87.00M134.68M166.56M155.25M82.02M77.52M75.07M103.57M117.90M9.04M7.50M2.62M1.39M1.35M0559.00K1.79M576.00K41.43M33.92M13.65M30.60M
R&D as % of Total Revenue--42616.03%1711.62%973.11%1117.28%850.38%705.64%355.13%318.06%309.91%422.52%2100.45%199.43%88.91%4.85%1.04%0.62%0.00%0.21%0.53%0.15%12.50%10.93%3.81%7.20%
Interest Expense0000823.00K577.00K523.00K93.00K5.68M6.05M6.04M6.02M6.00M9.35M36.89M51.80M52.42M43.60M23.95M18.66M18.33M19.07M15.79M19.16M22.21M16.70M
Interest Expense % of Total Revenue--0.00%0.00%9.21%4.79%2.67%0.42%24.60%24.83%24.95%24.57%106.95%206.27%437.47%96.02%39.24%20.07%9.18%7.15%5.44%4.87%4.77%6.17%6.19%3.93%

Balance Sheet

Currency: USD2000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets246.85M-192.72M125.45M286.02M224.84M262.42M161.98M236.16M181.39M331.20M258.78M368.58M681.25M521.65M424.07M379.00M367.34M548.19M724.83M999.57M926.39M1.23B1.24B1.30B1.64B
Total Liabilities22.66M-424.65M425.01M95.66M165.25M199.11M228.25M371.11M370.39M353.62M345.83M213.55M382.13M745.00M751.58M731.99M610.04M389.14M382.71M391.73M400.46M665.71M568.55M609.90M462.32M
Total Equity224.19M--231.93M-299.57M190.37M59.58M63.31M-66.26M-134.95M-188.99M-22.42M-87.05M155.03M299.12M-223.35M-342.64M-352.99M-242.86M153.58M313.50M607.84M414.74M565.79M674.96M691.16M1.17B
Cash--108.80M35.75M101.41M49.79M72.39M86.43M92.28M47.54M163.33M44.78M94.85M143.51M96.80M159.18M118.02M73.34M62.42M278.10M246.49M201.53M291.05M193.51M304.96M550.94M
Total Debt--36.05M7.87M4.40M1.88M625.00K536.00K172.94M172.96M172.78M172.57M172.50M287.50M725.64M733.13M716.09M599.36M382.86M377.12M410.52M394.76M544.07M449.08M451.10M269.02M
Net Debt---72.75M-27.88M-97.01M-47.91M-71.76M-85.90M80.66M125.42M9.44M127.79M77.65M143.99M628.84M573.95M598.08M526.03M320.44M99.02M139.03M193.23M253.02M255.56M146.13M-281.92M

Cash Flow

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-58.60M-31.68M-47.82M-58.65M-104.79M-104.37M-99.91M-58.06M-75.14M-88.34M-127.95M-129.60M-130.72M10.13M60.98M141.75M223.53M257.46M313.11M363.81M201.73M141.06M188.69M196.93M
Investing Cash Flow51.58M-13.61M-100.37M3.34M-18.58M110.59M-67.37M1.74M-40.31M-55.82M-58.28M-219.58M-65.06M159.17M-4.58M-23.24M3.52M-18.00M-314.94M43.72M-56.63M-66.76M-63.79M40.50M
Financing Cash Flow66.71M-27.76M213.85M3.68M145.97M7.83M173.12M11.59M231.25M25.60M236.31M397.84M149.07M-106.92M-97.57M-163.19M-237.97M-23.78M-29.79M-452.50M-55.57M-171.84M-13.45M8.55M
Capital Expenditure6.99M763.00K2.08M3.44M5.71M9.82M1.03M744.00K861.00K3.63M2.59M87.73M689.00K7.00K278.00K12.00K12.00K12.00K13.00K1.30M67.00K411.00K270.00K10.50M
Free Cash Flow-65.59M-32.44M-49.91M-62.09M-110.50M-114.19M-100.94M-58.81M-76.00M-91.97M-130.54M-217.34M-131.41M10.12M60.71M141.75M223.53M257.45M313.10M362.51M201.66M140.65M188.42M186.43M
Dividends Paid---------00056.99M87.33M960.00K281.00K80.00K11.00K00-96.28M--
FCF to OCF111.92%102.41%104.36%105.87%105.45%109.41%101.03%101.28%101.15%104.11%102.02%167.69%100.53%99.93%99.54%100.00%100.00%100.00%100.00%99.64%99.97%99.71%99.86%94.67%
Dividend Paid to FCF---------0.00%0.00%0.00%-43.37%862.61%1.58%0.20%0.04%0.00%0.00%0.00%-68.45%--

Earnings

Report DateFeb 16, 2005May 4, 2005Jul 27, 2005Oct 27, 2005Feb 9, 2006Apr 27, 2006Jul 27, 2006Oct 26, 2006Feb 8, 2007Apr 26, 2007Jul 26, 2007Oct 25, 2007Feb 14, 2008Apr 21, 2008Jul 24, 2008Oct 23, 2008Feb 12, 2009Apr 22, 2009Jul 23, 2009Oct 27, 2009Feb 11, 2010Apr 21, 2010Jul 22, 2010Oct 21, 2010Feb 15, 2011Apr 28, 2011Jul 28, 2011Oct 27, 2011Feb 9, 2012Apr 26, 2012Jul 31, 2012Oct 30, 2012Feb 12, 2013Apr 25, 2013Jul 25, 2013Oct 24, 2013Feb 6, 2014May 6, 2014Aug 6, 2014Oct 30, 2014Feb 18, 2015May 6, 2015Jul 29, 2015Oct 28, 2015Feb 3, 2016Apr 28, 2016Jul 28, 2016Oct 27, 2016Feb 9, 2017Apr 27, 2017Jul 26, 2017Oct 25, 2017Feb 8, 2018Apr 26, 2018Jul 26, 2018Oct 31, 2018Feb 6, 2019May 1, 2019Jul 24, 2019Oct 30, 2019Feb 5, 2020Apr 29, 2020Jul 29, 2020Oct 28, 2020Feb 3, 2021Apr 28, 2021Jul 28, 2021Oct 27, 2021Feb 9, 2022Apr 27, 2022Jul 27, 2022Nov 9, 2022Feb 28, 2023May 9, 2023Aug 2, 2023Nov 1, 2023Feb 29, 2024May 8, 2024Jul 31, 2024Nov 6, 2024Feb 26, 2025May 6, 2025Aug 6, 2025Nov 5, 2025Mar 4, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate-0.45-0.55-0.60-0.60-0.72-0.68-0.71-0.64-0.63-0.67-0.66-0.61-0.55-0.48-0.49-0.36-0.36-0.35-0.34-0.34-0.32-0.29-0.25-0.25-0.28-0.27-0.27-0.33-0.381.02-0.42-0.39-0.41-0.38-0.54-0.78-0.50-0.51-0.58-0.12-0.12-0.08-0.06-0.040.020.080.130.200.220.280.290.330.490.530.550.420.650.360.420.370.500.360.320.420.40-0.010.290.430.410.480.442.240.230.230.260.270.230.170.240.270.410.330.500.460.570.430.560.49
EPS Actual-0.56-0.59-0.60-0.71-0.79-0.86-0.70-0.63-0.63-0.82-0.75-0.53-0.54-0.49-0.44-0.34-0.26-0.29-0.35-0.35-0.35-0.35-0.28-0.29-0.25-0.28-0.31-0.37-0.450.93-0.42-0.37-0.33-0.39-0.37-0.44-0.46-0.62-0.18-0.19-0.14-0.09-0.07-0.040.040.040.130.130.220.150.300.280.480.270.490.440.600.310.340.360.420.420.330.460.550.840.900.900.140.440.620.54-0.980.420.020.180.760.46-0.550.120.26-0.740.771.081.940.470.59-
Surprise-24.44%-7.27%0.00%-18.33%-9.72%-26.47%1.41%1.56%0.00%-22.39%-13.64%13.11%1.82%-2.08%10.20%5.56%27.78%17.14%-2.94%-2.94%-9.38%-20.69%-12.00%-16.00%10.71%-3.70%-14.81%-12.12%-18.42%-8.82%0.00%5.13%19.51%-2.63%31.48%43.59%8.00%-21.57%68.97%-58.33%-16.67%-12.50%-16.67%0.00%100.00%-50.00%0.00%-35.00%0.00%-46.43%3.45%-15.15%-2.04%-49.06%-10.91%4.76%-7.69%-13.89%-19.05%-2.70%-16.00%16.67%3.13%9.52%37.50%8500.00%210.34%109.30%-65.85%-8.33%40.91%-75.89%-526.09%82.61%-92.31%-33.33%230.43%170.59%-329.17%-55.56%-36.59%-325.12%54.00%134.78%238.68%9.30%5.36%-
TimingAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.50B
Enterprise Value1.15B
Trailing P/E4.81
Forward P/E8.54
PEG Ratio0.25
Price / Sales3.41
Price / Book1.19
EPS4.31
Book Value16.98
Revenue (TTM)440.00M
Gross Profit (TTM)319.75M
EBITDA195.39M
Profit Margin81.19%
Operating Margin43.28%
Return on Equity36.68%
Return on Assets6.95%
Shares Outstanding72.25M
Shares Float67.65M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 35.00
  • Buy
    1

Ownership Breakdown

Institutions
109.21%
Insiders
1.01%
Retail / Other
0.00%

Top Institutional Holders

  • BlackRock Inc
    11.31M15.65%
  • Dimensional Fund Advisors, Inc.
    4.49M6.22%
  • Vanguard Portfolio Management, LLC
    4.22M5.85%
  • Renaissance Technologies Corp
    4.06M5.61%
  • Vanguard Capital Management, LLC
    3.14M4.35%
  • State Street Corp
    3.06M4.24%
  • Millennium Management LLC
    2.54M3.52%
  • Systematic Financial Management LP
    2.02M2.80%
  • Geode Capital Management, LLC
    1.93M2.67%
  • Boston Partners Global Investors, Inc
    1.93M2.67%
  • Sarissa Capital Management LP
    1.89M2.62%
  • Arrowstreet Capital Limited Partnership
    1.89M2.61%
  • Bank of America Corp
    1.62M2.24%
  • The Goldman Sachs Group Inc
    1.59M2.21%
  • Marshall Wace Asset Management Ltd
    1.50M2.08%
  • American Century Companies Inc
    1.50M2.07%

Top Fund Holders

  • iShares Core S&P Small-Cap ETF
    4.27M5.91%
  • Vanguard MStar Total Stk Mkt Idx Invest
    2.23M3.09%
  • iShares Russell 2000 ETF
    1.93M2.67%
  • Vanguard Small Cap Index
    1.61M2.23%

Dividends

20153×
0.25Sep 8, 20150.25Jun 10, 20150.25Mar 10, 2015
20142×
0.25Nov 21, 20140.25Aug 26, 2014

Stock Splits

  • Jun 3, 20141241:1000